Cadralazine (BioDeep_00000624663)

   


代谢物信息卡片


N-{6-[ethyl(2-hydroxypropyl)amino]pyridazin-3-yl}ethoxycarbohydrazonic acid

化学式: C12H21N5O3 (283.16443160000006)
中文名称: 卡达拉嗪
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCN(CC(C)O)C1=NN=C(C=C1)NNC(=O)OCC
InChI: InChI=1S/C12H21N5O3/c1-4-17(8-9(3)18)11-7-6-10(13-15-11)14-16-12(19)20-5-2/h6-7,9,18H,4-5,8H2,1-3H3,(H,13,14)(H,16,19)

描述信息

C - Cardiovascular system > C02 - Antihypertensives > C02D - Arteriolar smooth muscle, agents acting on > C02DB - Hydrazinophthalazine derivatives
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

同义名列表

2 个代谢物同义名

Cadralazine; N-{6-[ethyl(2-hydroxypropyl)amino]pyridazin-3-yl}ethoxycarbohydrazonic acid



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • H Ueno, M Takata, S Tomita, S Oh-hashi, K Yasumoto, H Inoue. The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors. Journal of cardiovascular pharmacology. 1997 Nov; 30(5):643-8. doi: 10.1097/00005344-199711000-00015. [PMID: 9388047]
  • M Wysocki, O K Andersson, B Persson, U Bagge, M Braide. Hemorheologic effects of vasodilation in essential hypertension. Angiology. 1996 Sep; 47(9):869-78. doi: 10.1177/000331979604700905. [PMID: 8810653]
  • J F Marichal, P Brunel, J B Lecaillon, J Godbillon, B Faller, P Brignon, J Ménard. Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily. European journal of drug metabolism and pharmacokinetics. 1992 Jul; 17(3):213-20. doi: 10.1007/bf03190148. [PMID: 1490491]
  • P Brunel, T T Guyene, H Howald, J Ménard. Arterial and endocrine effects of a combination of an angiotensin converting enzyme inhibitor and a vasodilator in normotensive healthy volunteers. Journal of cardiovascular pharmacology. 1991 Aug; 18(2):175-81. doi: 10.1097/00005344-199108000-00001. [PMID: 1717776]
  • J B Lecaillon, J P Dubois, T Darragon, M Motolese, A Racine, F Ducret, D Grouberman, D Cordonnier, J Chanard, M Glorioso. Pharmacokinetics of cadralazine in a large group of hypertensive patients chronically treated with cadralazine: advantage over a conventional study in a small group of patients. Therapeutic drug monitoring. 1991 Mar; 13(2):103-8. doi: 10.1097/00007691-199103000-00003. [PMID: 2053115]
  • M Andersson, A Hanson, G Englund, B Dahlbäck. Inhibition of complement components C3 and C4 by cadralazine and its active metabolite. European journal of clinical pharmacology. 1991; 40(3):261-5. doi: 10.1007/bf00315206. [PMID: 2060562]
  • P Brunel, J B Lecaillon, T T Guyene, P Imhof, J Ménard. Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects. British journal of clinical pharmacology. 1990 May; 29(5):503-9. doi: 10.1111/j.1365-2125.1990.tb03672.x. [PMID: 2190629]
  • P Brunel, J B Lecaillon, P Imhof, J Menard. [Influence of acetylation phenotype on the pharmacokinetics and pharmacodynamics data of cadralazine in normotensive subjects]. Archives des maladies du coeur et des vaisseaux. 1989 Jul; 82(7):1257-60. doi: NULL. [PMID: 2510657]
  • G Ferni, G Bonardi, M Lombroso, C Semeraro, L Dorigotti. Renal function studies with cadralazine in conscious dogs: a comparison with hydralazine. Pharmacological research. 1989 Mar; 21(2):211-22. doi: 10.1016/1043-6618(89)90240-5. [PMID: 2664751]
  • G Leonetti, J Parini, M Visconti, R Gradnik. Pharmacokinetics of cadralazine in hypertensive patients. European journal of drug metabolism and pharmacokinetics. 1988 Oct; 13(4):295-300. doi: 10.1007/bf03190093. [PMID: 3243325]
  • M C Rouan. Microbore liquid chromatographic determination of cadralazine and cephalexin in plasma with large-volume injection. Journal of chromatography. 1988 Apr; 426(2):335-44. doi: 10.1016/s0378-4347(00)81960-x. [PMID: 3392145]
  • T Nishimori, T Nishimura, F Kobayashi, D Nakano, Y Fukuda, H Sakonjyo, J Nakanishi, A Kimura, H Tsuji, T Higashio. [Effects of cadralazine on the respiration, circulation, kidney, autonomic nervous system, digestive system, blood and so on]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 1988 Apr; 91(4):221-36. doi: 10.1254/fpj.91.221. [PMID: 3391446]
  • Y Terauchi, S Watari, S Ishikawa, K Takeyama, Y Sekine, M Hashimoto, T Hayashi. Pharmacokinetics of an active cadralazine metabolite in plasma and blood vessels of spontaneously hypertensive rats. Arzneimittel-Forschung. 1988 Feb; 38(2):237-9. doi: NULL. [PMID: 3370071]
  • H Emilsson. High-performance liquid chromatographic determination of cadralazine in human plasma and urine. Journal of chromatography. 1988 Jan; 424(1):119-28. doi: 10.1016/s0378-4347(00)81082-8. [PMID: 3366823]
  • T Yukimura, K Miura, M Tanaka, T Higashio, S Sakaguchi, K Kuroda, K Yamamoto. Effects of cadralazine on systemic blood pressure, renal function and plasma renin activity in anesthetized dogs. Arzneimittel-Forschung. 1988 Jan; 38(1):25-8. doi: NULL. [PMID: 3284531]
  • Y Terauchi, S Watari, S Ishikawa, M Nakao, T Negoro, A Kagemoto, Y Sekine, M Hashimoto. Determination of ISF-2405, an active metabolite of cadralazine, in plasma and tissues by radioimmunoassay. Journal of pharmacobio-dynamics. 1987 Dec; 10(12):758-66. doi: 10.1248/bpb1978.10.758. [PMID: 3451960]
  • B Persson, G Granerus, M Wysocki, T Hedner, O K Andersson. Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics. European journal of clinical pharmacology. 1987; 31(5):513-8. doi: 10.1007/bf00606622. [PMID: 2881788]
  • S A Hauffe, J P Dubois, P R Imhof. Human pharmacokinetics of cadralazine: a new vasodilator. European journal of drug metabolism and pharmacokinetics. 1985 Jul; 10(3):217-23. doi: 10.1007/bf03189745. [PMID: 4085523]
  • H Schütz, J W Faigle, W Küng, W Theobald. Disposition and pharmacokinetics of cadralazine and individual metabolites in man. European journal of drug metabolism and pharmacokinetics. 1985 Apr; 10(2):147-53. doi: 10.1007/bf03189709. [PMID: 4043143]
  • T Crolla, F Santini, M Visconti, G Pifferi. High-performance liquid chromatographic separation of cadralazine from its potential metabolites and degradation products. Quantitation of the drug in human plasma and urine. Journal of chromatography. 1984 Sep; 310(1):139-49. doi: 10.1016/0378-4347(84)80075-4. [PMID: 6501510]
  • S A Hauffe, J P Dubois. Determination of cadralazine in human plasma and urine by high-performance liquid chromatography. Journal of chromatography. 1984 May; 290(?):223-30. doi: 10.1016/s0021-9673(01)93577-0. [PMID: 6736162]
  • H Schütz, J W Faigle. Multiple inverse isotope dilution assay for cadralazine and four metabolites in biological fluids. Journal of chromatography. 1983 Dec; 281(?):273-80. doi: 10.1016/s0021-9673(01)87885-7. [PMID: 6365939]
  • G Bonardi, E Rossi, M Pellegatti. [14C]cadralazine: absorption, distribution and excretion in rat and dog. European journal of drug metabolism and pharmacokinetics. 1983; 8(1):25-33. doi: 10.1007/bf03189578. [PMID: 6861793]